Background Single low doses of primaquine, when added to artemisinin-based combination therapy, might prevent transmission of Plasmodium falciparum malaria to mosquitoes. We aimed to establish the activity and safety of four low doses of primaquine combined with dihydroartemisinin-piperaquine in male patients in Mali.
Introduction
In the past decade, great progress has been made in the control of malaria through widespread access to and use of artemisinin-based combination therapy and insecticidetreated bednets. 1 Although malaria trans mission has been substantially reduced, 2 elimination is unlikely to be achieved with further scale-up of conventional methods in most settings in Africa. 3 New tools and strategies to reduce malaria transmission are necessary to maintain the gains of malaria control and push towards elimination. 4 In settings of low transmission and drug resistance, WHO 5 recommends single doses of 0·25 mg/kg of primaquine as an addition to standard artemisinin-based combination therapy to prevent onward transmission of Plasmodium falciparum infections to anopheline mosquitoes. Primaquine, an 8-aminoquinoline, has a unique drug action against mature P falciparum gametocytes, the sexual stages of the parasite responsible for onward transmission. 5 However, the widespread use of primaquine is hindered by safety concerns of dose-dependent haemolysis in people who are defi cient in glucose-6-phosphate dehydrogenase (G6PD). G6PD deficiency is the most common inherited enzyme defi ciency globally and is estimated at a community prevalence of 10-15% in much of malaria-endemic Africa, rising to much higher levels in certain specifi c communities. 6 Although recommendations are available, no formal dose-fi nding experiments have been done with a standardised infectivity assay to assess single doses of primaquine alongside artemisinin-based combination therapy. Recommendations are based on a review of historical infectivity trials 7 from 158 individual gametocytaemic individuals treated with plasmoquine or primaquine in diff erent studies with diff erent vectors and diff erent drug exposures. WHO's recommendation was not supported by the statement "Strong recommendation, high quality evidence" typical of recommendations for antimalarial use, and national malaria control programme managers expressed reluctance to implement this policy until modern data were available.
There have been no formal assessments of the effi cacy of single low doses of primaquine in reducing mosquito infection rates when added to artemisinin-based therapy. The fi rst formal primaquine dose-fi nding study concluded that low densities of P falciparum gametocytes detected by molecular methods persist after single low doses of primaquine. That study did not test the new WHO recommended low dose, but concluded that 0·10 mg/kg was inferior to the standard 0·75 mg/kg primaquine dose when given in combination with artemetherlumefantrine. 8 Importantly, to our know ledge, the infectivity of low-density gametocytes after primaquine in combination with an artemisinin-based combination therapy has not been established. Molecular gametocyte detection methods could lead to false conclusions about residual transmission potential if these tools detect nontransmissible gametocytes. 9 Deter mination of the lowest effi cacious dose of primaquine is of great importance to reduce the risk of dose-dependent haemolysis. 10 In this study we aimed to establish activity for diff erent doses of primaquine through repeated assessments of human infectivity to mosquitoes alongside sensitive molecular gametocyte detection and quantifi cation.
Methods

Study design and participants
We did a single-blind, dose-ranging, adaptive randomised, phase 2 trial of single low doses of primaquine in boys and men infected with P falciparum malaria. The protocol is available online. This study was done in two phases (details in appendix p 1). In the fi rst phase, we optimised the membrane feeding assay and assessed three primaquine dose groups. The data safety monitoring committee and study team then reviewed the infectivity and safety results
Research in context
Evidence before this study We searched PubMed on Sept 18, 2015, with the terms "primaquine" and "malaria, falciparum", "primaquine" and "gametocyte" or "primaquine" and "transmission". We identifi ed no randomised controlled trials of single low doses of primaquine with endpoints of gametocyte or transmission endpoints published after the dose-fi nding study by Eziefula and colleagues (2014) . In that study, one low dose of primaquine was added to artemether-lumefantrine combination therapy with investigators measuring duration of Plasmodium falciparum gametocytaemia with Pfs25 mRNA quantitative nucleic acid sequence-based amplifi cation (QT-NASBA) as the primary outcome measure for effi cacy. The authors concluded that single low-dose primaquine at 0·4 mg/kg had similar gametocytocidal effi cacy compared with 0·75 mg/kg, the single primaquine dose recommended by WHO for P falciparum until 2012, whereas they found a dose of 0·1 mg/kg did not show non-inferiority. However, no assessments of transmissibility of gametocytes were done, which was highlighted as an important limitation. The best available evidence on the transmission-blocking eff ects of primaquine was based on infectivity data from 158 individual gametocytaemic individuals treated with plasmoquine or primaquine in diff erent studies with diff erent vectors and diff erent drug exposures. A pooled analysis of these data supported the use of primaquine at a single dose lower than 0·75mg/kg.
Added value of this study
To our knowledge, our study is the fi rst dose-fi nding study of single low-dose primaquine that uses mosquito feeding assays, a resource-intensive but necessary method to obtain conclusive infectivity assessments. In individuals with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme function, doses of primaquine of 0·25 mg/kg and 0·5 mg/kg resulted in signifi cant decreases in infectivity to mosquitoes on day 2. Our fi ndings support WHO's recommendation for single-dose primaquine at 0·25 mg/kg to prevent malaria transmission along with artemisinin-based combination therapy dihydroartemisinin-piperaquine.
Implications of all the available evidence
Single low doses of primaquine should be rolled out, especially in areas where national malaria control programme managers have requested that contemporary dose-fi nding studies be carried out. Studies are warranted on the safety of single low doses of primaquine in individuals who are defi cient in G6PD.
For the protocol see http://www. shrinkingthemalariamap.org/ primaquine-dose-escalationstudy See Online for appendix from the fi rst phase and selected two additional primaquine dose groups to be tested sequentially in the second phase. We recruited participants from the town of Oulessebougou and its surrounding villages in Mali, at the Clinical Research Centre of the Malaria Research and Training Centre (MRTC) of the University of Bamako, Mali. Malaria transmission is high and seasonal in this setting-an incidence rate of about two episodes per year in children younger than age 5 years.
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Inclusion criteria included male sex (to reduce the risk of haemolysis through incorrect classifi cation of G6PD status, which more commonly occurs in heterozygote female individuals), age of 5-50 years, having at least two P falciparum gametocytes per 500 white blood cells on thick fi lm microscopy (corresponding to ≥32 gametocytes per μL assuming 8000 white blood cells per μL of blood), a haemoglobin concentration of 80 g/L or higher, and a normal G6PD test result via colorimetric quantifi cation (OSMMR2000-D G-6-PD, R&D Diagnostics, Papagos, Greece). We excluded participants who had taken malaria drugs within 7 days of screening, had known allergies to the study drugs, had serious or chronic illness, or had diagnosed cardiac arrhythmias. All participants older than 18 years provided written informed consent before screening and enrolment. We required parental consent for participants younger than 18 years, with children aged 12-17 years also providing assent for inclusion.
Participants were compensated for time and travel. 
Randomisation and masking
Treatment allocations were randomly generated and assigned to a list of prespecifi ed participant identifi er (ID) numbers by a UCSF investigator using a computer program (Excel). This investigator created sealed, opaque envelopes with participant ID number on the outside and treatment allocation on the inside of the envelope. Enrolled participants were sequentially assigned a participant ID number. The site pharmacist in Mali opened the sealed envelope corresponding to the participant ID number and provided the allocated treatment regimen. In the fi rst phase, participants were randomly assigned (1:1:1) into three primaquine dose groups-0 mg/kg (control), 0·125 mg/kg, and 0·5 mg/kg-in block sizes of six. In the second phase, participants were sequentially assigned (1:1) and enrolled fi rst into 0·25 mg/kg primaquine group and then into the 0·0625 mg/kg primaquine group when full. Block size was concealed from investigators.
Study investigators assessing outcomes were masked to treatment group assignment. Participants were allowed to ask the study physician which treatment they received and so were not masked to allocation. Additionally, participants could have recognised the presence of primaquine through the bitter taste of the active pharmaceutical ingredient.
Procedures
After collection of day 0 samples, the study pharmacist provided primaquine (Sanofi , Laval, QC, Canada) through crushing 15 mg primaquine tablets and dissolving them in 15 mL of drinking water. Primaquine was administered to the nearest mL, as described elsewhere. 8 Each participant received an oral dose of primaquine according to their group assignment after a fatty snack (biscuits) to prevent gastrointestinal side-eff ects. All participants were given the fi rst tablet of a 3 day course of dihydroartemisininpiperaquine (Eurartesim, Sigma-Tau, Italy). Dihydroartemisinin-piperaquine (320 mg and 40 mg per tablet) was given as per manufacturer's guidelines once a day for 3 days with the following considerations for weight: 13 kg to <24 kg one tablet; 24 kg to <36 kg two tablets; 36 kg to <75 kg three tablets; and 75-100 kg four tablets. All treatment doses were directly observed by the study pharmacist and his assistant.
Participants attended follow-up appointments at the clinic at 2 h, 6 h, 12 h, and 1 day, 2 days, 3 days, 7 days, 14 days, and 28 days after the start of treatment. Mosquito infectivity was measured at day 0 (pre-treatment), day 1, day 2, and day 7. Venous blood was collected in heparin tubes kept at 37°C and placed in a membrane feeding system within 1 min of being collected. Three cups of 30 Anopheles gambiae mosquitoes each (90 mosquitoes in total except at day 0 when 180 mosquitoes were used) were fed the parti cipant's blood for 15-20 min with methods previously described.
12 Blood-fed mosquitoes were then transported the next day to the insectary in Bamako, Mali, where they were kept until dissection on day 7 post-feeding and examination for oocysts in 1% mercurochrome. The presence of oocysts was confi rmed by a second microscopist. Mosquito infectivity from the person to the mosquito was defi ned as the proportion of dissected mosquitoes with oocysts. Additionally, participants were classifi ed as infectious (yes vs no) if at least one dissected mosquito had at least one oocyst.
Haemoglobin was measured before treatment (day 0) and at each follow-up visit (days 1, 2, 3, 7, 14, and 28) using HemoCue (AB Leo Diagnostics, Helsingborg, Sweden). Adverse events were assessed actively during follow-up visits (days 1, 2, 3, 7, 14, and 28) and passively through the availability of study clinicians 24 h per day, 7 days per week, without charge during the follow-up period, including free transportation if needed. Adverse events were graded by severity (mild, grade 1; moderate, grade 2; or severe, grade 3, in intensity, and whether they were considered serious by the treating physician) and categorised by their relationship with the study drugs (unrelated or probably not, possibly, probably, or defi nitely related). Additionally, we recorded the duration of adverse event, any actions taken, and outcome of adverse events. 14 in primary infectivity analysis 2 excluded due to enrolment before optimisation 10 in infectivity subgroup analysis 2 excluded due to enrolment before optimisation 4 excluded due to zero baseline infectivity 15 in gametocyte analysis 1 excluded due to no follow-up visit 15 in haemoglobin and AE analysis 1 excluded due to no follow-up visit 12 in primary infectivity analysis 3 excluded due to enrolment before optimisation 1 excluded due to no follow-up visit 1 excluded due to allocated dose not received 8 in infectivity subgroup analysis 1 excluded due to enrolment before optimisation 3 excluded due to no follow-up visit 1 excluded due to allocated dose not received 4 excluded due to zero baseline infectivity result 16 
Second phase
Gametocyte density measurements were done on day 0 (pre-treatment), 2 h, 6 h, and 12 h after treatment, and on days 1, 2, 3, 7, 14, and 28. Blood slides stained with Giemsa were double read by expert research microscopists over 500 fi elds for quantifi cation of gametocytes and asexual stages. 100 μL of whole blood was collected in L6 buff er (Severn Biotech, Kidderminster, UK), total nucleic acid was extracted using a MagNAPure LC automatic extractor (Total Nucleic Acid Isolation KitHigh Performance; Roche Applied Science, Indianapolis, IN, USA) followed by RQ1 DNaseI digest (Promega, Sunnyvale, CA, USA), cDNA synthesis (High Capacity cDNA Reverse Transcription Kit, Applied Biosystems, Foster City, CA, USA), and molecular quanti fi cation of gametocytes using Pfs25 mRNA quantitative real-time (qRT) PCR, as described elsewhere. 13 Gametocyte concentration was estimated using a reference trendline of cultured mature stage V gametocytes (NF54 strain 14 ) that was serially diluted using tenfold dilutions from 10⁶ to 10 gametocytes per mL.
Genomic DNA available from total nucleic acids extracted for gametocyte quantifi cation were used for genotyping cytochrome P450 2D6 (CYP2D6). Samples from all participants were tested, and participants with a suffi cient amount and quality of DNA were genotyped for CYP2D6 *2, *3, *4, *6, *7, *8, *9, *10, *11, *15, *17, *18, *19, *20, *29, *40, and *41 alleles using Openarray technology on a QuantStudio 12K Flex RT PCR system (Life Technologies, Carlsbad, CA, USA). The CYP2D6 copy number was determined with a TaqMan copy number assay targeting intron 2 on the QuantStudio 12K Flex system, and CYP2D6 metaboliser status was inferred from the genotypes using both classic and activity score methods.
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Outcomes
The primary effi cacy outcome was the mean within-person percentage change in mosquito infectivity per group, 2 days after primaquine administration. Prespecifi ed secondary effi cacy endpoints were the presence of oocysts in mosquito at other timepoints (day 1 and day 7), the proportion of individuals infecting at least one mosquito (at all timepoints), gametocyte prevalence, and density determined microscopically and by molecular methods, and asexual parasite prevalence and density. Safety outcomes were adverse events and haemolysis, for which we calculated the average within-person change in 0·125 mg/kg group 69·4% (21·4 to 100); p=0·057 94·9% (84·6 to 100); p=0·045 100% (100 to 100); p=0·142 0·25 mg/kg group 87·8% (70·4 to 100); p=0·014 99·2% (97·6 to 100); p=0·0082 100% (100 to 100); p=0·052 0·5 mg/kg group 91·5% (73·4 to 100); p=0·0064 87·6% (60·2 to 100); p=0·030 95·1% (84·2 to 100); p=0·11
Data are mean (95% CI), unless stated otherwise. Reduction in infectivity measured as the average change in proportion of dissected mosquitoes with oocysts. haemoglobin, the proportion of participants with a 25% or greater drop in haemoglobin, and the proportion of participants with a haemoglobin level of 80 g/L or lower during follow-up. As a prespecifi ed secondary analysis, we aimed to explore the genetics of cytochrome P450, the enzyme responsible for the activation of primaquine to its active metabolite for the cure of vivax malaria.
Statistical analysis
Sample size calculations assumed that the proportion of people that would infect at least one mosquito was 0·80, and that on average the proportion of mosquitoes that would become infected was 0·25. We originally calculated that we would need 30 participants per group to have 80% power to detect a 90% reduction in the number of mosquitoes with oocysts after treatment with a 0·05 signifi cance. However after assay optimisation we revisited the sample size calculation and found that, after allowing for 10% loss to follow-up, we needed 15 individuals per group. For the primary outcome we calculated the average within-person percent change in infectivity and accompanying 95% CI for each treatment group. To make pairwise comparisons of the change in infectivity and change in haemoglobin concentration after treatment (control vs each treatment group) we used the one-sided non-parametric Wilcoxon rank-sum test. Additionally, we used the one-sided exact probability test to compare the proportion of infectious individuals in each treatment group to the control group at each visit, and the one-sided non-parametric Wilcoxon rank-sum test to compare the median proportion of mosquitoes infected in each treatment group to the median proportion of mosquitoes infected in the control group at each visit.
qRT-PCR gametocyte density and prevalence at individual treatment days were compared between individual primaquine groups and the control group using linear (log 10 density) and logistic (prevalence) regression models with treatment group and baseline qRT-PCR gametocyte density as independent variables. qRT-PCR gametocyte density was used to generate the area under the curve (AUC) of gametocyte density versus time, which was compared between the treatment and control groups as described previously 17 with log 10 transformed AUC as dependent variable in a linear regression model with treatment group and baseline qRT-PCR gametocyte density as independent variables. The association between the proportion of infected mosquitoes and qRT-PCR gametocyte density was determined by Spearman correlation coeffi cient before and after treatment.
Analyses of gametocytes were done among all enrolled participants, excluding those who violated the protocol. Analysis of the change in infectivity (primary endpoint) included only patients who completed the study after optimisation of the infectivity assay, who had a pre-treatment infectivity measurement and at least one follow-up infectivity measurement, and who were given the correct primaquine dose (primary infectivity analysis sample). In addition, we did a change in infectivity analysis including only participants who infected at least one mosquito pre-treatment. Analyses of adverse events and the change in haemoglobin (safely endpoint) after treatment were restricted to participants with a pre-treatment measurement and at least one follow-up visit (total enrolled sample with a follow-up visit). Analyses were done with Stata version 12.1.
A data safety monitoring committee oversaw the study, and the study was monitored by an external clinical trials monitoring group, Agence Africaine de Recherche en Santé Humaine. Dakar, Senegal. The study was registered with ClinicalTrials.gov, number NCT01743820.
Role of the funding source
The funder of the study had no role in the data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had fi nal responsibility for the decision to submit the publication. 
Results
We screened 1485 individuals, enrolling 81 participants into the study between Jan 19, 2013, and Dec 20, 2014 (fi gure 1, table 1). Of those screened, most were not eligible due to the absence of gametocytes assessed by microscopy (n=1159). 77 participants (95%) were retained through the day 28 follow-up visit; no participants were lost to follow-up. In phase one (Jan 2, 2013, to Feb 22, 2014), 16 participants were randomly assigned to the control group, with 17 randomly assigned to the 0·125 mg/kg primaquine group and 17 to the 0·5 mg/kg primaquine group. One participant assigned to the 0·125 mg/kg primaquine group was inadvertently given 0·375mg/kg. This error was discovered at the day 0 visit, and the participant was retained in follow-up through day 28 and included in the haemoglobin and adverse event analysis but excluded from the change in infectivity analyses. In phase two (Aug 5, 2014, to Nov 28, 2014), 15 patients were sequentially allocated to the 0·25 primaquine group and then 16 were sequentially allocated to the 0·0625 mg/kg primaquine group.
The study was halted on Feb 13, 2013, after eight participants had been recruited because pre-treatment infection rates in the mosquitoes were unacceptably low. Assay optimisation and protocol amendments were completed and the study restarted enrolment on the Sept 17, 2013 (appendix p 1). After optimisation 79% (58 of 73) of pre-treatment membrane feeding experi ments resulted in at least one infected mosquito, and 24% (1763 of 7301) of mosquitoes became infected. Overall, we used 32 040 mosquitoes in feeding experiments, of which 24 009 (75%) survived to be dissected on day 7, resulting in 2043 infection-positive results (appendix p 2).
The primary analysis of the change in infectivity was done in the 71 participants in the primary analysis sample. We recorded signifi cantly reduced mean withinperson infectivity on day 2 in participants assigned to the 0·25 mg/kg (92·6% [95% CI 78·3-100; p=0·0014) and the 0·5 mg/kg groups (75·0% [45·7-100]; p=0·014) compared with the control group (11·3% [-27·4 to 50·0]; table 2). Among individuals who were infectious before treatment (infected at least one mosquito; subgroup sample [n=57]), within-person infectivity after treatment was largely reduced and signifi cantly diff ered from controls at day 2 in those assigned to the 0·125 mg/kg, 0·25 mg/kg, and 0·5 mg/kg groups (table 2) .
The proportion of individuals that infected at least one mosquito 2 days after treatment was signifi cantly reduced in the 0·125 mg/kg, 0·25 mg/kg, and 0·5 mg/kg dose groups (fi gure 2A; appendix p 2). Analysis of the median number of mosquitoes infected at each timepoint by dose group showed signifi cantly fewer mosquitoes becoming infected on day 2 in dose groups 0·125 mg/kg, 0·25 mg/kg, and 0·5 mg/kg compared with control group (fi gure 2B; appendix p 2). No participants in either the 0·125 mg/kg group or the 0·25 mg/kg group infected mosquitoes at day 7, and one participant in the 0·5 mg/kg primaquine group infected a single mosquito on day 7 after treatment.
All study participants who received the correct dose of primaquine (n=80) were gametocyte positive on Pfs25 mRNA qRT-PCR at enrolment, with a signifi cantly higher gametocyte density at enrolment in the 0·25 mg/kg primaquine group compared with the control group (appendix p 3; p=0·013). After adjustment for baseline gametocyte density, gametocyte prevalence was signifi cantly lower in the 0·5 mg/kg primaquine group than the control group on day 7, day 14, and day 28 (fi gure 3A). On day 28, gametocyte prevalence was lower in all participants in primaquine dose groups compared with the control group (fi gure 3A). Gametocyte density decreased during follow-up for all treatment groups (appendix p 3); the density of gametocytes in gametocyte-positive individuals was signifi cantly lower in groups assigned to primaquine doses of 0·125 mg/kg and lower from day 3 onwards, after adjusting for baseline density (fi gure 3B; appendix p 3). The AUC of gametocyte density over time was signifi cantly lower in all primaquine groups compared with the control group, after adjust ment for baseline density (p≤0·027 for 0·125 mg/kg vs control; appendix p 3). Before treatment, Pfs25 mRNA qRT-PCR gametocyte density was strongly associated with mosquito infection rates (n=73; Spearman correlation coeffi cient 0·56, 95% CI 0·44-0·66; p<0·0001; fi gure 4, appendix p 3). This association was no longer apparent on day 1 (n=71; r=0·07, 95% CI -0·17 to 0·30; p=0·57), day 2 (n=71; r=0·17, 95% CI -0·07 to 0·39; p=0·16), or day 7 (n=46; r=0·15, 95% CI -0·15 to 0·42; p=0·34) after initiation of treatment (fi gure 4, appendix p 3). Analyses of change in haemoglobin and of adverse events were restricted to participants with at least one follow-up visit (n=79). Overall median haemoglobin concentration on day 0 was 124 g/L (range 86-162), on day 7 was 116 g/L (range 85-179), and on day 28 was 123 g/L (range 102-173). Within-person changes in haemoglobin concentration were not signifi cant in any of the treatment groups compared with the control group at any timepoint (appendix p 4). During followup, no participants had a haemoglobin concentration lower than 80 g/L or had a 25% or greater drop in haemoglobin after treatment.
42 (53%) participants had an adverse event during follow-up (table 3) . The number of participants that had an adverse event did not signifi cantly diff er between groups (Fisher's exact test, p=0·48). Most adverse events (69 [87%]) were mild (grade 1), with ten (13%) of moderate severity (grade 2). No adverse events resulted in stopping study treatment or study participation. One participant in the 0·5 mg/kg group reported transitory dark urine (mild, grade 1) on day 1, which was considered unrelated to study drug because this participant's haemoglobin concentration was 142 g/L on day 0 and remained higher than this concentration until day 28. One participant in the control group reported shortness of breath (mild, grade 1), which was resolved and considered unrelated to study treatment. There were no severe adverse events or serious adverse events detected during the study, and all adverse events resolved during study follow-up.
We successfully genotyped CYP2D6 DNA for 43 (53%) of 81 participants. 18 Two participants were poor metabolisers (one in the control group and one in the 0·0625 mg/kg group) and four were intermediate metabolisers by both conventional phenotype inference. Five were intermediate metabolisers by the conventional method, but extensive metabolisers by activity score, 30 were extensive metabolisers by both the conventional method and activity score, and two were ultra-rapid metabolisers (one in the 0·0625 mg/kg group and one in the 0·25 mg/kg group). CYP2D6 typing failed for the participant who received 0·5 mg/kg primaquine and was infectious on day 7. CYP2D6 genotypes did not diff er signifi cantly between treatment groups (Fisher's exact test, p=0·35).
Discussion
We show that although gametocytes persist on molecular qRT PCR, malaria infectivity is reduced by greater than 90% on day 2 and day 7 after one 0·25 mg/kg primaquine dose and artemisinin-based combination therapy. Among participants that infected mosquitoes pretreatment, we saw a greater than 90% reduction in infectivity with primaquine doses of 0·125 mg/kg or higher by day 2 and in all groups given single low doses of primaquine by day 7. We observed no serious adverse events or evidence of haemolysis in our study population of G6PD-functional boys and men. Treatment with artemisinin-based combination therapy results in a rapid reduction in P falciparum gametocyte carriage and transmissibility. In our study, 79% of all participants with microscopically detectable gametocytes infected at least one mosquito before treatment, similar to fi ndings from a meta-analysis on membrane feeding assays. 19 With dihydroartemisinin-piperaquine treatment alone (ie, the control group), this proportion was reduced to 54% by day 2 and 23% by day 7, representing reductions in infectivity of 27% and 66%, respectively (fi gure 2A). The residual transmission after dihydroartemisininpiperaquine treatment has been observed before 20 and is partly explained by the limited eff ect of the artemisinin component against mature (stage V) gametocytes that were present before treatment. 21 Single low doses of primaquine greater than 0·125 mg/kg potentiate the transmission-reducing eff ect of dihydroartemisininpiperaquine. Only one individual was infectious on day 7 after primaquine treatment among those given doses of primaquine of 0·125 mg/kg or higher and this person infected only one mosquito. Our fi ndings of near complete prevention of transmission in all individuals given 0·125 mg/kg of primaquine or higher, when given in combination with dihydroartemisinin-piperaquine, are consistent with historical data in which primaquine was administered in conjunction with other antimalarial drugs. 7 Future studies should explore whether the transmission-blocking eff ects of single low doses of primaquine depend on the type of artemisinin-based combination therapy they are co-administered with.
Gametocytes were detected in all treatment groups after treatment. Notably, the presence of gametocytes and gametocyte density were not associated with infectivity after treatment. Recent studies on the effi cacy of single low doses of primaquine frequently used gametocyte prevalence as the primary endpoint as a surrogate for infectivity. 22, 23 In our study population most individuals in the control group retained low densities of gametocytes measured by Pfs25 mRNA qRT PCR until the end of follow-up on day 28. Although primaquine shows a dosedependent eff ect on gametocyte prevalence, there was a clear discordance between gametocyte prevalence and density estimates and the likelihood of mosquito infection after treatment. Before treatment, gametocyte densities were strongly associated with the proportion of infected mosquitoes, but this association was lost during days post-treatment. Older studies had similar fi ndings with gametocytes being detectable by microscopy for several days after primaquine but failed to infect mosquitoes. 21 Our results support the view that available tests to assess gametocyte density cannot be used to estimate post-treatment infectivity.
The gametocyte density and infectivity mismatch shown in our fi ndings might be explained by preferential measurement of female gametocytes in our methods. Pfs25 mRNA transcripts, which we used to measure gametocytes in this study, could be female specifi c. 9, 24 Recently, primaquine was postulated to disproportionally kill male gametocytes 9 and thereby prevent transmission that depends on the presence of both male and female gametocytes in permissive concentrations. Methylene blue, another antigametocyte drug, is more potent against male gametocytes than against female gametocytes. 25 It is conceivable that our quantifi cation of gametocytes is female-biased and becomes progressively more so after treatment. This could explain the absence of mosquito infectivity at later timepoints after primaquine when male gametocytes might have been eff ectively cleared. We tested samples with a new qRT PCR that detects male Pfs230p transcripts; 24 however, the transcript levels of Pfs230p are much lower than those for Pfs25 14 and we were unable to detect male gametocytes in most baseline samples (data not shown). Future studies should establish whether primaquine has a higher potency against male gametocytes and is a potential explanation for our fi ndings of gametocytes being present, yet non-infective. Findings from our study leave unaddressed the question of whether there is a diff erential eff ect of antimalarial treatment on male and female game tocytes. Until better indicators of gametocyte infectivity become available (which will probably consist of sensitive, sex-specifi c, quantitative molecular There were no severe or serious adverse events. All events were self-reported. Mild events were defi ned as those causing no or mlnlmal Interference with usual social and fu nctional activities; moderate events as those causing greater than minimaI interference; and severe events as those causing inability to perform usual social and functional activities. *Defi ned as probably or defi nitely related to study treatment. gameto cyte detection methods), the transmissionblocking properties of antimalarial drugs can only be assessed by mosquito feeding assays. 5, 7 The labour intensiveness of membrane feeding assays limits the number of sites at which trials with a transmission endpoint can be done and limits the study size that can be used. Although our study had a relatively small sample size, our fi ndings more than double the available evidence on single low doses of primaquine. Available recommendations are based on retrospective analysis of nine studies and a total of 65 individuals who received single low doses of primaquine in combination with an artemisinin-based combination therapy. 7 The present study includes 24 009 mosquito observations from 284 experiments before and at three timepoints after single low doses of primaquine. Infectivity in our study was maximised through enrolment of high-density gametocyte carriers that are highly infectious compared with average malaria-infected individuals who have much lower gametocyte densities and are considerably less infectious. 26 In individuals with low gametocyte densities, who comprise a considerable proportion of the human infectious reservoir for malaria, 27 single low doses of primaquine are likely to be even more effi cacious than we reported for our study population. A fraction of gametocyte carriers are not infectious to mosquitoes. 19 In our study, 14 (20%) of 71 participants were not measured to have infectivity pre-treatment and 11 (17%) of them never infected mosquitoes during the whole study period. This failure to infect mosquitoes despite relatively high gametocyte densities could be caused by gametocyte fi tness or host factors such as naturally acquired immune responses to gametocyte antigens that could reduce transmission effi ciency, as well as limitations of the membrane feeding assay. 19 These factors are unlikely to have aff ected our comparisons of within-person changes in infectivity or comparisons of dose groups.
Our adaptive study design resulted in two phases of enrolment, the second of which was not randomised. We consider it unlikely that this shortcoming has aff ected our conclusions on the transmission-blocking properties of the diff erent doses of primaquine since our main analysis was based on within-person changes in infectivity; other comparisons between treatment groups were adjusted for baseline infectivity or baseline gametocyte density, where appropriate.
Residual transmission after single low doses of primaquine is of particular importance considering possible inter individual variation in primaquine meta bolism. 18 In our study, we successfully genotyped 53% of participants for cytochrome P450 2D6 (CYP2D6). This low success rate is a result of the availability of small volume blood samples that were collected for gametocyte detection and not for detailed human genetic analyses. One single participant received the highest dose of single low doses of primaquine tested (0·5 mg/kg) yet remained infectious, infecting one mosquito on day 7. CYP2D6 typing failed for this individual; whether this participant was a CYP2D6 poor metaboliser is therefore unknown.
This study was carried out in a relatively small population of men and boys with normal functioning G6PD in Mali. Thus, we are unable to generalise the fi ndings to young children, G6PD-defi cient people, women, and other African populations or people residing outside subSaharan Africa, in whom G6PD variants that are associated with more severe G6PD enzyme defi ciency might occur. We chose boys and men with normal G6PD function with haemoglobin concentrations 80 g/L before treatment because their risk of haemolysis after exposure to single low doses of primaquine would be low. A previous study in Uganda showed a transient reduction in haemoglobin concentrations in individuals who were genotypically G6PD-defi cient but were screened as having normal functioning G6PD by fl uorescence spot test. 28 We did not observe any signifi cant decreases in haemoglobin or increases in adverse events in primaquine groups compared with the control group. Future studies should address the safety profi le of single low doses of primaquine in larger populations that include G6PD-defi cient participants to inform the highest tolerable dose without previous testing for G6PD defi ciency. WHO recommends use of 0·25 mg/kg primaquine without previous G6PD testing in areas of low transmission or areas threatened by artemisinin resistance. 7 However, most antimalarial drugs are dispensed based on age-based categories, removing the need to weigh patients before treatment. If single low doses of primaquine are to be rolled out, similar categories will be needed to defi ne a range of dosing that is both safe and effi cacious. 10 A second more challenging safety issue is the safety of primaquine in pregnancy. 29 This issue might better be assessed through active pharmacovigilance of the use of single low doses of primaquine in programme use 29 or safety assessments of mass drug administration studies in which early stage pregnancies might be inadvertently treated and later followed-up to note pregnancy outcomes. 30 Our fi ndings support WHO's recommendation for the addition of one-time primaquine at a dose of 0·25 mg/kg in combination with dihydroartemisin-piperaquine for prevention of P falciparum trans mission. In community treatment campaigns, a simplifi ed delivery of single low doses of primaquine might involve age-based dosing to replace the current weight-based recommended dose regimen. This regimen could result in relative over-dosing and under-dosing of fractions of the population. In this context, our study provides valuable information on the dose of 0·125 mg/kg. Although not signifi cant in the primary analysis, in secondary analyses the 0·125mg/kg dose showed potent and signifi cant effi cacy in preventing and reducing transmission to mosquitoes by day 2.
Further studies to assess the highest-tolerable single primaquine dose in G6PD-defi cient individuals are needed to defi ne the therapeutic range for simplifi ed delivery of the intervention. Community studies can then be done to show the impact of single low doses of primaquine on malaria transmission in populations that might benefi t from this intervention, including in areas of low malaria transmission intensity.
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